Nanomedical Diagnostics, a U.S-based producer of graphene biosensors for pharmaceutical and biotherapeutics research, has announced a headquarters relocation, effectively tripling its space from 5,200 to 16,500 square feet.
This past year has seen exponential growth, both domestically and internationally, for the sales of our drug discovery platforms. We’re in the great position of having to move to a new space to accommodate expanded production and R&D, says Nanomedical Diagnostics CEO, Ross Bundy. Our new building enables better operational efficiencies for our production lines and brings departments that were formerly separated in different locations together under one roof. This allows for better collaboration and innovation as we launch new products and grow our staff.
2019 promises to be an exciting year for the company, continues Mr. Bundy. We’re launching a new high-throughput drug discovery product early in the year and are in the process of hiring in all departments to support increased sales. We are also expanding our line of industrial OEM graphene sensors for use by partners in diverse industries and are thrilled to find a space that can accommodate our projected growth over the next few years.